Before revision: We introduce DeepNovoV2, the state-of-the-art neural networks based model for de novo peptide sequencing.
After revision: Personalized cancer vaccines are envisioned as the next generation rational cancer immunotherapy. The key step in developing personalized therapeutic cancer vaccines is to identify tumor-specific neoantigens that are on the surface of tumor cells. A promising method for this is through de novo peptide sequencing from mass spectrometry data. In this paper we introduce DeepNovoV2, the state-of-the-art neural networks based model for de novo peptide sequencing.